Affiliation:
1. Department of Pharmacy Practice, State University of New York at Buffalo, USA.
Abstract
Delavirdine is a nonnucleoside reverse transcriptase inhibitor with in vitro activity against human immunodeficiency virus type 1 (HIV-1) that is currently being evaluated in combination regimens with various nucleoside analogs, including didanosine. Due to the pH-dependent solubility of delavirdine, the buffering agents in didanosine formulations may reduce delavirdine absorption. To evaluate the potential interaction between these agents, 12 HIV-infected patients (mean [+/- standard deviation] CD4+ cell count, 304 +/- 213/mm3) were enrolled in a three-way crossover single-dose study. Didanosine (125 to 200 mg given as buffered tablets) and delavirdine mesylate (400 mg) pharmacokinetics were evaluated when each drug was given alone (treatments A and B, respectively), when the two drugs were given concurrently (treatment C), and when didanosine was given 1 h after delavirdine (treatment D). Delavirdine exposure was reduced by concurrent administration of didanosine. The maximum drug concentration in serum (Cmax) was reduced from 7.22 +/- 4.0 to 3.51 +/- 1.9 microM, and the area under the concentration-time curve from 0 h to infinity (AUC0-->infinity) was reduced from 22.5 +/- 14 to 14 +/- 5.7 microM.h. The extent of N-dealkylation, as indicated by the ratio of the N-dealkylated delavirdine AUC0-->infinity to the delavirdine AUC0-->infinity, was unchanged across study treatments (P = 0.708). Reductions in didanosine exposure were observed during concurrent administration with delavirdine with a Cmax reduction from 4.65 +/- 2.0 to 3.22 +/- 0.59 microM and an AUC0-->infinity reduction from 7.93 +/- 3.9 to 6.54 +/- 2.3 microM.h. Thus, concurrent administration of delavirdine and didanosine may reduce the AUC0-->infinity of both drugs, although the clinical significance of this reduction is unknown. Administration of delavirdine 1 h before didanosine avoided the interaction. Due to the single-dose nature of this study, these findings require further evaluation at steady state.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference31 articles.
1. Bristol-Myers Squibb. 1993. Videx package insert. Bristol-Myers Squibb Princeton N.J.
2. Effect of fluconazole on pharmacokinetics of 2~,3~-dideoxyinosine in persons seropositive for human immunodeficiency virus;Bruzzese V. L.;Antimicrob. Agents Chemother.,1995
3. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel;Carpenter C. C. J.;JAMA,1996
4. Chong K. T. P. J. Pagano and R. R. Hinshaw. 1993. A novel BHAP U-90152 is synergistic with 3~-azido-2~ 3~-dideoxythymidine (AZT) and 2~ 3~-dideoxycytidine (ddC) against HIV-1 replication in vitro abstr. POA25-0606 p. 235. In Abstracts of the 9th International Conference on AIDS. University of Berlin Berlin Germany.
5. Treatment for human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitibine;Collier A. C.;N. Engl. J. Med.,1996
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment;Expert Opinion on Drug Metabolism & Toxicology;2019-10-03
2. Clinical Drug-Drug Interaction Data: Effects of Antiretroviral Agents on Co-administered Drugs;Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs;2016
3. Clinical Drug-Drug Interaction Data: Effects of Co-administered Drugs on Pharmacokinetics of Antiretroviral Agents;Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs;2016
4. Delavirdine;Meyler's Side Effects of Drugs;2016
5. Which Metabolites Circulate?;Drug Metabolism and Disposition;2013-03-01